AMENDMENT TO CONSULTING AGREEMENT
THIS FIRST AMENDMENT to the CONSULTING AGREEMENT (the “First Amendment”) is made and entered into on this 31st day of May, 2025 (the “First Amendment Effective Date”), by and between BioCryst Pharmaceuticals, Inc., a Delaware Corporation and Anthony Doyle
RECITALS
WHEREAS, BioCryst and Anthony Doyle entered into a Consulting Agreement (the “Agreement”) having an effective date of April 9, 2025; and
WHEREAS, both parties wish to extend the term of the Agreement.
NOW, THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, BioCryst and Anthony Doyle, intending to be legally bound, have agreed to amend the terms of the Agreement as follows:
The Term of the Agreement shall be extended through December 31, 2025, and shall automatically continue thereafter on a month-to-month basis until terminated by either party upon thirty (30) days’ written notice.
Except as expressly amended hereby, the Agreement shall remain in full force and effect in accordance with its terms.
IN WITNESS WHEREOF, the parties have executed this Amendment as of the first date above written.
| | | | | |
| Anthony Doyle | BioCryst Pharmaceuticals, Inc. |
Signature: /s/ Anthony Doyle | Signature: /s/ Alane Barnes |
| Name: Anthony Doyle | Name: Alane Barnes |
| Title: Consultant | Title: Chief Legal Officer |